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ABSTRACT: Prions are believed to propagate when an assembly of prion
protein (PrP) enters a cell and replicates to produce two or more fibrils,
leading to an exponential increase in PrP aggregate number with time.
However, the molecular basis of this process has not yet been established in
detail. Here, we use single-aggregate imaging to study fibril fragmentation
and elongation of individual murine PrP aggregates from seeded aggregation
in vitro. We found that PrP elongation occurs via a structural conversion
from a PK-sensitive to PK-resistant conformer. Fibril fragmentation was
found to be length-dependent and resulted in the formation of PK-sensitive
fragments. Measurement of the rate constants for these processes also
allowed us to predict a simple spreading model for aggregate propagation
through the brain, assuming that doubling of the aggregate number is rate-
limiting. In contrast, while α-synuclein aggregated by the same mechanism, it
showed significantly slower elongation and fragmentation rate constants than PrP, leading to much slower replication rate.
Overall, our study shows that fibril elongation with fragmentation are key molecular processes in PrP and α-synuclein aggregate
replication, an important concept in prion biology, and also establishes a simple framework to start to determine the main
factors that control the rate of prion and prion-like spreading in animals.
■ INTRODUCTION
Prion diseases are fatal neurodegenerative conditions of various
vertebrate species, characterized by conversion of the normal
form of the predominantly α-helical host protein PrPC, into the
β-sheet-enriched abnormal conformer PrPSc. According to the
prion hypothesis, the transmissible prion agent comprises
principally PrPSc.1 Several lines of experimental evidence have
collectively provided strong support for the prion hypothesis.
These include the generation of PrP transgenic mice that
develop spontaneous neurodegenerative disease that is trans-
missible2−4 and in vitro generation of infectious prions.5,6
Prion diseases are an important model for protein misfolding
neurodegenerative conditions in general, since several of these
diseases, including Alzheimer’s disease (AD) and Parkinson’s
disease (PD), show features of prion-like transmission in
experimental settings, evidenced by transcellular spread of
misfolded disease-specific protein.7,8 While the injection of α-
synuclein fibrils has been shown to lead to prion-like spreading
in animal models of PD,9 there is currently no quantitative
framework to extrapolate these results to humans, and hence it
remains to be established if prion-like spreading occurs in PD.
Prion replication occurs by a nucleation-dependent polymer-
ization reaction, whereby growth of aggregated PrP nuclei is
followed by fast elongation through recruitment of misfolded
PrP monomers to the protein assemblies.10 Several molecular
events are proposed to play a key role in this process, such as
fibril fragmentation11−13 (Figure 1a). Fibril fragmentation
increases the number of protein assemblies by generating
multiple fragments, and thus providing new ends for monomer
addition, a process that becomes important in the later stage of
assembly aggregation.13 Fibril fragmentation has been
demonstrated to accelerate prion replication in yeast prion
Sup3511,14 and Ure2,15 as well as α-synuclein (αS) in PD,16
while few insights have been provided from mammalian prion
studies.17 Significantly, there is no clear evidence that
mammalian prions show a similar phenomenon of fragmenta-
tion during aggregation. Therefore, it is important to
determine the mechanism and kinetics of how PrP aggregates
grow and amplify, since these events will provide fundamental
insights into how prions might spread in the brains of
individuals affected by prion diseases.
Dissecting the mechanism of prion propagation in vivo is
difficult given the molecular and cellular complexity of the
mammalian brain. As a consequence, this process has been
increasingly studied with recombinant prion protein in vitro.
Compared with conventional biochemical and biophysical
approaches, single-molecule fluorescence microscopy serves as
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a powerful tool by resolving the behavior of individual protein
aggregates that may be averaged in ensemble experiments.
Recently, we have developed “single-aggregate” fluorescence
imaging to visualize protein aggregates through the use of
sensitive total internal reflection fluorescence (TIRF) micros-
copy in combination with thioflavin T (ThT).18 This method
provides direct observation of the low-populated species such
as oligomers, which are naturally heterogeneous, transient, and
metastable during aggregation.16,19−22 It also enables us to
quantitatively measure the change in the number of individual
aggregates as a function of time. Furthermore, as ThT
molecules bind and unbind from the protein aggregates in
equilibrium, this approach allows protein assemblies to be
imaged for extended time periods without photobleaching and
for biochemical assays, such as proteinase K (PK) resistance
measurements, to be performed on individual aggregates.
Here, we have adapted the single-aggregate fluorescence
imaging to visualize the aggregation process of recombinant
PrP and αS under native conditions. In this present study, we
have quantitatively measured PrP and αS aggregation in vitro
as a function of time. This has allowed us to determine, for the
first time to our knowledge, the elongation and fragmentation
rate constants for PrP aggregation through the use of a kinetic
modeling approach. These parameters thus enabled us to
predict the spread of PrP through the brain based on a simple
model. We also show that αS replication is likely to follow the
same elongation−fragmentation mechanism with a signifi-
cantly slower elongation and fragmentation rate than PrP. In
addition, we find that during the aggregation reaction, both
PrP and αS convert from a PK-sensitive to PK-resistant
conformer. The fragmentation rate increases with fibril length,
and this process results in the formation of PK-sensitive
fragments. This study demonstrates our ability to quantita-
tively compare the prion-like properties between PrP and αS,
and reveals the key role of fibril fragmentation and elongation
in prion and prion-like replication.
Figure 1. Schematic description of the molecular processes of fibril formation and the experimental setup. (a) Amyloid fibril formation begins with
slow primary nucleation that involves a range of structurally diverse intermediates, followed by fast growth of fibrils. The fibrils can break into
smaller fragments and act as new templates for further growth. (b) In the bulk solution-seeded measurements (left), PrP aggregates were incubated
in a 1.5 mL centrifuge tube. At various time points, aliquots were removed from the reaction mix and transferred to a solution containing ThT, and
the aggregates subsequently diluted to a nanomolar concentration. The PrP aggregates were imaged on a TIRF microscope with a 3 × 3 image grid
at 3 random positions (i.e., 27 simultaneous images). The acquired images were analyzed with a Matlab-based script to identify individual
aggregates (see Experimental Procedures in the Supporting Information for details). For the surface-seeded measurements (right), preformed
soluble or insoluble seeds were separated by centrifugation and then adsorbed onto a glass coverslip. After removal of residual solution, fresh PrP
monomers and ThT were added to the glass coverslip and slide chamber sealed to prevent fluid evaporation. Images of individual aggregates were
acquired over time in a single 3 × 3 image grid with fixed fields of view at 37 °C (i.e., 9 simultaneous images). All the scale bars represent 2 μm.
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■ RESULTS
Kinetic Rate Constants of PrP Aggregation Can Be
Determined from Solution-Seeded Reactions under
Native Conditions. Kinetic rate constants for the elongation
and fragmentation process of amyloidogenic proteins can be
derived from quantitative measurements during aggregation.23
To acquire the kinetic parameters for PrP aggregation, we
performed a set of seeded reactions of murine recombinant
PrP in bulk solution under native conditions (Figure 1b, left).
To produce seeds, PrP aggregates were generated following
a previously published protocol.24 Small aggregates (Figure
S1a,b), as well as large fibrils (Figure S1c), were obtained after
48 h, when the reaction reached a plateau. The aggregate
mixture was then separated by centrifugation to obtain soluble
aggregates from the supernatant (soluble seeds), or insoluble
aggregates (insoluble seeds; acquired from sonication of the
fibrillary species after pellet resuspension). Prior to imaging
PrP seeds, we established optimal conditions where the
number of PrP aggregates adsorbed onto a glass surface was
proportional to their solution concentration (Figure S2), which
means the surface was not saturated by the aggregates.
Next, we carried out PrP aggregation using the soluble seed
in the reaction buffer (50 mM sodium phosphate buffer, pH
7.0) with a wide range of seed and monomer concentrations.
At defined time points during the seeded aggregation reaction,
aliquots were removed from the reaction mix, and the number
of PrP aggregates present quantified using ThT and TIRF
microscopy (Figure 1b, left). Seeded PrP aggregation was
found to proceed through exponential amplification, as shown
in Figure 2. We found that gentle shaking of the reaction mix
was required in order for PrP to form aggregates. This is
consistent with conditions used for QuIC experiments25 and
was possibly due to a fraction of the aggregates adsorbed on
the microcentrifuge tube surface. Interestingly, we also
observed fast disappearance of PrP aggregates after the
reaction reached a plateau. Through the use of transmission
electron microscopy (TEM), we observed that the PrP
aggregates that disappeared in TIRF images were ThT-inactive
and small fragments (<50 nm) (Figure S3) that probably
formed due to fragmentation.
To acquire kinetic parameters for PrP aggregation, the data
was globally fitted to a kinetic model for protein aggregation
that we have published previously.12,26 This model has two
parameters: the elongation rate constant, ke, and the
fragmentation rate constant, kf. When we consider the time
required for a single misfolded PrP aggregate elongate and
fragment to form two aggregates, the doubling time t2, is given
by
=t
k k m
ln2
(2 )e f
2
(1)
where m is the monomer concentration (see Experimental
Procedures in the Supporting Information for details). From
the global fit to the solution-seeded data (Figure 2c), the
product of ke and kf was found to be 0.06 M
−1 s−2 (Table 1).
According to eq 1, the doubling time t2 for PrP amplification
in a cell depends on the rate constants, ke and kf, as well as
subcellular PrPC concentration (m) at the cellular location
where PrPC-PrPSc conversion takes place. Since this conversion
site in cells is still debated,27−30 we assumed that PrP
aggregation occurs at the plasma membrane and the
corresponding local PrPC concentration is 60 nM (see
Supporting Information for details). Using the rate constants
obtained from the solution-seeded reaction with soluble seeds,
t2 was estimated to be 2.2 h for PrP assembly propagation on
the plasma membrane. In comparison, if PrP aggregation is
assumed to take place in the endosomal compartments, where
the local PrPC concentration is 15 nM, the estimated t2 would
slightly increase to 4.4 h, showing that t2 is not very sensitive to
the monomer concentration (Table 1).
PrP Fragmentation and Elongation Are Directly
Observed from Surface-Seeded Aggregation. Next, to
study the fragmentation kinetics of PrP, we performed surface-
seeded aggregation reactions under the same native conditions
as above, which allowed continual measurements of fixed fields
of view on a coverslip surface. Experiments were achieved by
adsorbing either the soluble or insoluble seed onto a glass
coverslip, removing the residual solution, followed by the
addition of PrP monomers into the reaction mix. Changes in
the morphology and the size of individual PrP aggregates were
visualized over time by continual imaging of the same fields of
view on a microscope stage at 37 °C (Figure 1b, right). We
followed more than 10 000 aggregates during surface-
seeded aggregation reactions using the soluble or insoluble
seeds, respectively. Interestingly, 8.7% (soluble) and 4.4%
(insoluble) of the PrP aggregates were observed to grow into
longer fibrils (Figure 3a, upper two panels, and Videos S1, S2),
while the majority of the existing PrP seeds showed no
detectable change in length. Consistent with the observation of
an increase in aggregate length, the ThT intensity of individual
aggregates increased with length both in soluble and insoluble
seeding cases (Figure S4a,b). The slower increase in the
average length for insoluble seeds compared to soluble seeds
could be due to structural difference of the seeds resulting in
different growth rates (Figure S4c).
Figure 2. Kinetics of solution-seeded PrP aggregation in 50 mM
sodium phosphate (pH 7.0). (a,b) The kinetics were measured by
taking aliquots at various time points from aggregation reaction mix
that was incubated at 37 °C with shaking at 200 rpm. (c,d) Fits of the
kinetic profiles. The y-axis was normalized to the maximum value of
each profile. The product of the rate constants, kekf, for solution-
seeded PrP aggregation was 0.06 ± 0.03 M−1 s−2. The error bars
represent standard deviations from three independent experiments.
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Strikingly, fragmentation events of PrP fibrils that involved
one fibrillar assembly breaking into two or more smaller-sized
fragments were directly observed. These fragments were shown
to be capable of growing into longer fibrils at later times
(Figure 3a, lower two panels, and Videos S3, S4). The
fragmentation events account for only 0.4% (soluble) and 0.9%
(insoluble) of the total events recorded for each type of seed.
In addition, a fraction of the fragmented PrP species
disappeared during the aggregation reaction, which suggested
that these small-sized assemblies were not detected by ThT.
This is in agreement with our finding from solution-seeded
experiments (Figure 2a,b) and TEM imaging (Figure S3) that
PrP aggregates can fragment into ThT-inactive species.
Centrifugation experiments demonstrated that fluorescence
imaging with ThT was able to detect PrP aggregates of 12-
mers or larger (Figure S5), which suggested the ThT-inactive
species were smaller in size.
Although a similar real-time imaging approach has
previously been used to follow fibril formation of β2-
microglobulin31 and Aβ,32 the molecular mechanism was not
discussed or quantified despite the importance in under-
standing prion propagation. To measure the kinetic rate
constants for PrP aggregation on a surface, we fitted the
average rate of increase of fibril length as a function of time
(Figure S4c). The fragmentation rate constants were estimated
as kf (soluble) ≥ 5 × 10−9 s−1 and kf (insoluble) ≥ 1.6 × 10−8 s−1 for
soluble and insoluble seeding, respectively. In contrast, the
elongation rate constants were estimated as ke (soluble) = 3.39 ×
104 M−1 s−1 and ke (insoluble) = 1 × 10
4 M−1 s−1 (Table 2). The
different rate constants for the soluble and insoluble seed is
likely to result from the different structures. It should be noted
that we used “ ≥ ” for kf values because of potential
underestimation, as there may be fragmentation events that
were unable to be detected as shown in Figure S3. We also
observed that the product of ke and kf for the soluble seed is
≥0.00017 M−1 s−2 in surface-seeded reaction, which is slower
than 0.06 M−1 s−2 in bulk solution-seeded reaction by 2 orders
of magnitude. This may reflect differences between aggregation
in solution and on the surface, but may also be due to the
under estimation of kf obtained in the surface-seeded
Table 1. Kinetic Parameters for PrP and αS Aggregation in Solutiona
protein ke (M
−1 s−1) kf (s
−1) kekf (M
−1 s−2) m (nM) t2 PK-sen to PK-res conversion half-time
PrP ∼104 b ∼10−6 b 0.06 ± 0.03 60 (PM) 2.2 ± 1.1 h <0.25 h
15 (EC) 4.4 ± 2.2 h
αS 43 ± 7 1.6 ± 0.2 × 10−10 6.9 ± 1.4 × 10−9 2000 (SN) 48 ± 2 day 39.5 ± 7.3 h
ake elongation rate constant; kf fragmentation rate constant; m local concentration of monomers in the cells; t2 doubling time required for a single
protein aggregate to replicate into two aggregates during aggregation. PM: plasma membrane; EC: endosomal compartments; SN: synapse. The
errors represent uncertainties of the fitting parameters given the dataset. bEstimate is within the same order of magnitude.
Figure 3. Direct measurement of PrP fibril elongation and fragmentation. (a) The representative examples of PrP elongation (upper panel, see
Videos S1, S2) and PrP fragmentation (lower panel, see Videos S3, S4) were recorded over a 6 h period during surface-seeded aggregation with
soluble seeds in 50 mM sodium phosphate (pH 7.0) at 37 °C. Individual particles were tracked over time by imaging with fixed fields of view every
5 min. The scale bars represent 2 μm. (b) Proteinase K (PK) resistance of PrP aggregates during surface-seeded aggregation. PK was added at
different times to the glass surface that contained the PrP aggregates and the slide chamber sealed to prevent fluid evaporation. The change in ThT
intensity of individual particles was followed by continual imaging with fixed fields of view at 37 °C incubation. PK resistance was calculated as the
fraction of the ThT intensity after 1 h proteolytic digestion compared to that seen at the start of the experiment.
Table 2. Kinetic Parameters for Surface-Seeded PrPa
seed type ke (M
−1 s−1) kf (s
−1)b kekf (M
−1 s−2)b PK-sen to PK-res conversion half-time
soluble seed 3.39 ± 0.04 × 104 ≥5 × 10−9 ≥0.00017 0.25 h
insoluble seed 1 × 104 ≥1.6 × 10−8 ≥0.00016
ake elongation rate constant; kf fragmentation rate constant. The errors represent uncertainties of the fitting parameters given the dataset.
bMeasured as the slowest value.
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experiments, resulting in a lower kekf. However, the slower
surface-seeded reaction allowed us to directly observe
fragmentation and also measure changes in PK resistance.
PrP Aggregates Undergo Structural Conversion from
PK-Sensitive to PK-Resistant Conformation. To assess the
susceptibility of PrP aggregates to Proteinase K (PK) digestion,
we carried out proteolytic digestion at single-aggregate level
during surface-seeded aggregation with soluble seeds. This was
achieved by the addition of PK at defined time points during
the seeded aggregation reaction and subsequent measurement
of the decrease of ThT intensity of individual PrP assemblies
induced by proteolytic digestion. Initially, the soluble seeds
were predominantly PK-sensitive (PK-sen), as very few PrP
assemblies remained detectable after 1 h digestion with PK.
With increasing time, more aggregates maintained high ThT
intensity after PK digestion (Figure 3b). This suggested that
accumulation of PK-resistant species (PK-res) occurred with
time and that a structural conversion occurred during PrP
aggregation. Furthermore, compared to PK-sen species, the
PK-res species possessed higher initial ThT intensity before PK
digestion, which indicated these assemblies were also larger in
size since the length-intensity relationship was demonstrated to
be linear (Figure S6).
Next, we quantified the fractions of the PK-sen and PK-res
species by fitting with 2D Gaussian functions and hence
acquired the kinetic profiles shown in Figure 4. The number of
PK-res aggregates showed a fast increase and reached a
maximum level after 1 h aggregation. This suggested a fast PK-
sen→ PK-res conversion reaction occurred with a half-time of
∼0.25 h (Table 1). As the replication rate of PrP was slower on
the surface due to lower kekf, this conversion rate on the surface
was likely to be slower than that in bulk solution, which is
expected to be <0.25 h.
Fragmentation of PrP Fibrils Follows a Length-
Dependent Mechanism and Is Accompanied by Loss
of PK Resistance. The fragmentation rate constant, kf, in our
kinetic model was calculated per monomer in an aggregated
assembly. A fibril may potentially fragment at random positions
along its length, and hence the rate of fragmentation would be
expected to increase with fibril length (i.e., a 1000-mer fibril is
expected to have fragmentation rate higher than the kf value by
1000-fold). Since very few studies have demonstrated the
molecular details of fibril fragmentation, we measured this
process on the coverslip surface to probe the length
dependence. Fragmentation of individual PrP fibrils was
followed continually over 72 h in fixed fields of view, and
the decrease in the average fibril length (i.e., fragmentation)
was measured. A higher fragmentation rate was revealed with
increasing fibril length (Figure 5a and S7). The kinetic profiles
were in good agreement with the PrP fibril fragmentation fits
based on our kinetic model, which suggested that the
fragmentation rate of a fibril is proportional to its fibril length,
and that our previous assumption was justified.
Next, we examined the susceptibility of fragmented PrP
fibrils to PK digestion at defined time points (Figure 5c).
Surprisingly, PrP fibrils rapidly lost resistance to PK despite
our observation that the number of PK-sen aggregates
remained approximately constant (Figure 5b). The PK-res
species that have peak intensity at 10 au became PK-sen, while
the less intense PK-sen species peaked at 5 au disappeared,
presumably due to fragmentation into smaller species that were
not ThT-active. This suggested that the PK-sen aggregates at
later times are more likely to be generated from the initially
PK-res fibrils by a structural conversion.
Aggregation of α-Synuclein Is Associated with
Slower Fragmentation Rate than PrP. Protein inclusions
of α-synuclein (αS) are the neuropathological hallmark of
Parkinson’s disease (PD) and related synucleinopathies
including dementia with Lewy bodies (DLB) and multiple
system atrophy (MSA). αS has been reported to exhibit
transcellular spread by a prion-like mechanism.33−35 Hence, we
investigated the propagation characteristics of human αS in
comparison with those associated with PrP replication. Seeded
or unseeded human αS aggregation reactions were performed
in bulk solution under native conditions to determine the
change in aggregate length with respect to time (Figure 1, left
and Figure 6a). In unseeded αS aggregation, we observed an
initial increase in the average aggregate length, followed by a
slow decrease at later times over a long period of several weeks.
The decrease of aggregate length was shown not to be due to
proteolysis (Figure S8), which suggested it is likely to result
from fragmentation of αS fibrils. To extract the kinetic
parameters of αS aggregation, we fitted the kinetic profiles and
estimated ke and kf for αS. With these values we calculated the
product of ke and kf of 6.9 × 10
−9 M−1 s−2, which is lower than
the equivalent value for PrP in solution by a factor of 107
(Table 1). Given the αS concentration of neuron synapses in
the mouse brain was estimated to be 2 μM,36 the derived
doubling time t2 for αS is 48 days. This suggested that the time
for αS to replicate was approximately 1000-fold longer than
that of PrP replication. This calculation provides a quantitative
approach to estimate to what extent αS is “prion-like” through
the kinetic parameters measured.
We also analyzed the PK resistance for αS assemblies at
defined time points during its aggregation (Figure 6b). It was
found that αS aggregates were initially PK-sensitive and
subsequently acquired PK resistance as the assemblies grew in
length into longer fibrils. Likewise, the fractions of the PK-sen
and PK-res species of αS were quantified by fitting with 2D
Figure 4. Structural conversion of PrP aggregates. Temporal change
in (a) the fraction and (b) the number of PK-sen and PK-res species
of surface-seeded PrP aggregates using soluble seeds. The data set
from Figure 2b were globally fitted to 2D Gaussian functions to
obtain the fraction of PK-sen and PK-res populations. (c) Intensity
distributions after PK-digestion for surface-seeded PrP aggregates at
different time points. The error bars represent standard deviations
from three independent experiments.
Journal of the American Chemical Society Article
DOI: 10.1021/jacs.8b08311
J. Am. Chem. Soc. 2018, 140, 14789−14798
14793
Gaussian functions and hence kinetic profiles acquired. The
fraction of PK-res aggregates increased rapidly and reached a
plateau after 2 days (Figure 7a), while the number of these
assemblies increased continuously over time (Figure 7b). The
conversion of αS aggregates from PK-sen to PK-res forms was
determined to have a half time of ∼39.5 h, which is in good
agreement with our previous FRET measurements.20 In
comparison with the half-time for PrP conversion, αS
aggregates required >100 fold more time for structural
conversion (Table 1) despite the fact that the aggregation
would appear to occur by a similar mechanism.
Estimation for the Spreading Time of PrP and αS in
the Brain. It has been demonstrated that the growth rate of
different strains in yeast prion Sup35 can be predicted by a
simple model which takes into account monomer concen-
tration, the rate of cell division, and the elongation and
fragmentation rates of different strains.14 With a similar model,
we previously estimated the spreading of tau replication in the
brain using experimentally measured kinetic parameters,
showing that tau accumulation in the brain is likely to follow
an exponential behavior resulting from fragmentation.23 Here,
we tested this spreading model with PrP and αS using the
kinetic parameters that we acquired in Table 1.
Sustainable spreading of protein aggregates in the cells
involves both effective seeding and amplification, as discussed
in our previous study.16 In this scenario, a single PrP aggregate
in a cell can grow and then fragment into two smaller
assemblies. The two assemblies thus act as new templates and
are able to enter neighboring cells in order to support
sustained spreading. Therefore, the accumulated number of
PrP aggregates is exponential and given by
= ·f n f( ) 2n0 (2)
where f 0 is the initial number of aggregates and n is the round
of doubling required to reach a final number of aggregates f(n).
On the basis of the rounds of doubling (n) and doubling time
(t2) in eq 1, one can calculate the hypothetical spreading time
(Tspreading) required to obtain a certain number of aggregates in
the brain:
= ·T n tspreading 2 (3)
Next, we asked how fast PrP aggregates would hypothetically
spread in the mouse brain based on our findings when a single
aggregate is effectively seeded on the plasma membrane.
According to the eq 2 and 3, we plotted the accumulation of
PrP aggregates as a function of time and then calculated
Tspreading (Figure S9a).
In a typical mouse brain, there are approximately 70 million
neurons. To obtain one PrP aggregate in every neuron on
average, it would take 2.4 days for a wild-type Prnp+/+ mouse
through exponential replication. For a Prnp+/− mouse (∼0.5×
PrP expression level) and a tg20 mouse (∼8× PrP expression
level), it would take 3.4 and 0.8 days, respectively (Table S1).
As we have discussed previously, PrP levels at different
conversion sites only have a mild effect upon t2, and hence do
not alter Tspreading to a great extent. The hypothetical
calculation of PrP spreading agrees with the experimental
incubation periods observed in mice models within 2 orders of
magnitude. The experimentally determined incubation periods
are 137 ± 1.5, 258 ± 24, and 59.5 ± 2 days for Prnp+/+,
Prnp+/−, and tg20 mice, respectively.37 Importantly, the relative
ratios of Tspreading between the three mouse strains (Prnp
+/−,
Prnp+/+, tg20) predicted from our model are very similar to
those from animal experiments.
With the same rationale, we repeated the above calculations
using the rate constants obtained for αS (Figure S9a). As we
obtained a t2 of 48 days for αS in the mouse brain, Tspreading was
predicted to be ∼3.4 years in order to spread through an entire
mouse brain (Table S1). This is in surprisingly good
agreement with the experimental results of 15 months
Figure 5. PrP fibril fragmentation. (a) Time-dependent change in average PrP fibril length, for a range of initial lengths. The data shown
correspond to the average of three independent experiments. (b) Proteinase K (PK) resistance of PrP aggregates during surface-seeded aggregation.
PK was added at different times to the glass surface that contained the PrP aggregates, and the slide chamber was sealed to prevent fluid
evaporation. The change in ThT intensity of individual particles was followed by continual imaging with fixed fields of view at 37 °C incubation. PK
resistance was calculated as the fraction of the ThT intensity after 1 h proteolytic digestion compared to that seen at the start of the experiment.
The error bars represent standard deviations from three independent experiments. (c) Temporal change in the fraction and the number of PK-sen
and PK-res species of PrP fragments as a function of time. The data set from (b) was globally fitted to 2D-Gaussian functions to obtain the fraction
of PK-sen and PK-res populations as a function of time.
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duration, which is required for 90% of the WT mouse brain
cells to acquire αS inclusions after intracerebral injection of the
human αS seed.38 Despite having significantly slower
elongation and fragmentation rates than PrP, our model
suggests that αS follows a similar prion-like mechanism of
spreading in vivo.
■ DISCUSSION
We have directly observed the elongation and fragmentation of
murine PrP. Although fragmentation has been proposed to be
an important factor for sustained prion replication, this is the
first time to our knowledge that fragmentation has been
directly observed. Our results show that amplification of the
number of PrP aggregates occurs by an elongation/
fragmentation mechanism, and PrP fibrils fragment with a
substantially higher rate compared with αS. Surface-seeded
experiments reveal fibril fragmentation rate is proportional to
fibril length. This suggests that larger-sized fibrils are more
likely to break and thus produce new templates for further
replication.
We also observed that during the aggregation process PrP
undergoes structural conversion from a PK-sen to PK-res
conformer. This is consistent with previous studies in mice
where PK-res and PK-sen PrP species accumulated during
prion propagation.7,37 However, in our experiments reported
here we observed that during fragmentation PrP fibrils rapidly
lose PK resistance, possibly due to destabilization of the
fibrillar structure. Our finding would argue that reversion of PK
resistance occurs when the fibrillar structure becomes fragile.
Despite the fragility of fibril fragments, they are able to form
new fibrils as directly observed on the surface and regain
resistance to PK. Our observations partly explain the
production of disease-related PK-sen species observed in
vivo.37,39−42 Fragmentation of large PrP fibrils at later times is
likely to produce more PK-sen segments and thus exceed the
formation of new PK-resistant fibrils, which is consistent with
the finding that the PK-sen species constitutes the majority of
total PrP level at the late stage of prion propagation in mice.37
Through determination of the rate constants, ke and kf, we
were able to calculate the t2 for PrP replication at the
physiological protein concentration in cells, and hence
establish a simple spreading model based on these kinetic
measurements. PrP replication shows unusually fast elonga-
tion/fragmentation and results in t2 = 2.2 h (Table 1), leading
to an estimate of the time to spread throughout the mouse
brain as a few days. The discrepancy between our prediction
and in vivo experimental data can be explained by several
cellular mechanisms that we did not consider in our spreading
model. These include organelle confinement and active
clearance and the degradation of misfolded proteins.43 The
presence of the lipid membrane has been shown to restrict the
motion of Aβ oligomers on the lipid membrane44, so since PrP
is a GPI-anchored protein predominantly found within lipid
rafts on the plasma membrane,45 it is likely that the rate of PrP
Figure 6. Kinetics of αS aggregation. (a) Kinetics of seeded- and
nonseeded solution-seeded α-synuclein aggregation in 50 mM sodium
phosphate buffer (pH 7.0). Reaction kinetics were measured by taking
aliquots at various time points from aggregation reaction mix that was
incubated at 37 °C with shaking at 200 rpm. The kinetic data
obtained were used to estimate the fragmentation and elongation rate
constants ke and kf, respectively. The product of rate constants kekf is
6.9 ± 1.4 × 10−9 M−1 s−2. The error bars represent standard
deviations from three independent experiments. (b) Proteinase K
(PK) resistance of αS aggregates. αS aggregates induced by sonicated
fibrils were incubated in a 1.5 mL centrifuge tube. At various time
points, aliquots were removed from the reaction mix and adsorbed
onto a glass coverslip. PK was added at different times to the glass
coverslip and slide chamber sealed to prevent fluid evaporation. The
change in ThT intensity of individual particles was followed by
continual imaging with the fixed fields of view at 37 °C incubation. PK
resistance was calculated as the fraction of the ThT intensity after 1 h
proteolytic digestion compared to that seen at the start of the
experiment.
Figure 7. Structural conversion of αS aggregates. Temporal change in
(a) the fraction and (b) the number of PK-sen and PK-res species of
αS aggregates as a function of time. The data set from Figure 6b were
globally fitted to 2D Gaussian functions to obtain the fraction of PK-
sen and PK-res populations as a function of time. (c) Intensity
distributions after PK-digestion at different time points.
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spreading in vivo may be also altered due to clustering and
slower diffusion on the membrane. PrP glycosylation has also
been demonstrated to decrease PrPSc amplification in PMCA
by 10−10 000 fold.46,47 Furthermore, specific cofactors would
appear to be necessary for faithful prion propagation in a
strain-specific manner,48 which appears to be a general
phenomenon that is not restricted to mammalian hosts.49
The effect of the above mechanisms on the rate of spreading is
not understood, and so it is not possible to include these
factors in our current kinetic model. However, these factors are
likely to decrease the rate of PrP spreading in vivo, by either
reducing the replication efficiency or increasing t2. Our data
also show that αS replication is similar to PrP, occurring
through an elongation−fragmentation mechanism at much
slower rates. This provides a quantitative approach to estimate
the prion-like property of αS based on its aggregation kinetics.
On the basis of the observation of longer t2, we predict that αS
aggregates would spend significant time in cells without
degradation as has recently been observed.50
Our kinetic approach may also explain the differences in
amplification rate of different prion strains. The diversity of
prion strains represent different conformational states of PrPSc
within the same genotype that directly influence host range
and clinicopathological features of prion diseases in the
affected host.51 On the basis of eq 1, if a given prion strain
(F) has faster t2 (i.e., higher ke or kf value) than a slow strain
(S), the number of prion strain F would be substantially
greater than that of prion strain S after multiple rounds of
doubling (see Supporting Information for calculations). For
example, if prion strain F has a t2 10% lower than prion strain S
(i.e., approximately 20% higher in kekf), after 26 rounds of
doubling (the number of doubling rounds needed for one
aggregate of strain F to replicate so there is an aggregate in
every neuron in a mouse brain, see Table S1) , a 5-fold excess
of F-strain aggregates will be produced. Therefore, small
differences in kinetic rate constants or replication efficiency
would appear to be able to contribute to an explanation of the
diversity in prion strains.
In summary, we have directly observed spontaneous fibril
fragmentation and elongation for PrP and αS in vitro and
hence measured their fragmentation and elongation rate
constants. During the aggregation of PrP and αS, these
proteins undergo structural conversion from PK-sen to PK-res
conformers. Furthermore, fragmentation of the aggregated
forms of these proteins follows a length-dependent mechanism
leading to the formation of PK-sen fragments. The measure-
ment of the kinetic parameters involved in these processes has
allowed us to estimate the rate of spread of prion and prion-
like aggregates in the brain. Our model explains some of the
key features of prion diseases and makes quantitative
predictions that can be tested experimentally about the
spreading of PrP and other prion-like proteins such as αS.
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